Lung Cancer
Conference Coverage
NSCLC survival comparable with accelerated and conventional RT
BOSTON – Patients with stage II or III non–small-cell lung cancer with comorbidities that make them poor candidates for surgery or chemotherapy...
News
Racial gaps persist in lung cancer trial enrollment
Key clinical point: Elderly women, blacks, Asians, Pacific Islanders, and Hispanics are all still underrepresented in lung cancer clinical trials...
News
Recommendations for Cancer Moonshot overlook a few issues, YSC says
News
New anticancer drugs linked to increased costs, life expectancy
From the Journals
Whole brain radiotherapy not beneficial for NSCLC metastasis
Whole brain radiotherapy provided no clinically significant benefit for most patients with metastatic non–small-cell lung cancer.
From the Journals
Pneumonitis with nivolumab treatment shows common radiographic patterns
Among 20 cancer patients treated with this PD-1 inhibitor who developed pneumonitis, cryptogenic organizing pneumonia was seen in 13.
News
Biomarker-driven targeted therapy feasible for NSCLC
Key clinical point: Biomarker-driven targeted therapy was found feasible for heavily pretreated, metastatic NSCLC. Major finding: The primary...
News
Adding ipilimumab to chemotherapy did not boost overall survival in small-cell lung cancer
Key clinical point: The anti–CTLA-4 antibody ipilimumab (Yervoy) missed its primary endpoint in a trial of patients with extensive-stage small-...
News
Ceritinib effective when NSCLC progresses despite crizotinib
Key clinical point: Ceritinib produced meaningful, durable responses in heavily pretreated patients with NSCLC who had advanced disease, including...